TGFBI protein, BIGH3 Human recombinant protein

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

BIGH3 Human recombinant protein

Catalog Number: 10-663-46225

Buy TGFBI protein -

Size:

Trial Size Available

Related Product Names:

- TGFBI protein; TGFBI; BIGH3; BIGH3 Human
- Transforming growth factor-beta-induced protein ig-h3, Beta ig-h3, Kerato-epithelin, RGD-containing collagen-associated protein, RGD-CAP, TGFBI, BIGH3, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, CDGG1.; Beta ig-h3; Kerato-epithelin; RGD-containing col; Transforming growth factor-beta-induced protein ig-h3

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: TGFBI	Gene Name Synonym: BIGH3
Gi #: N/A	NCBI Acc #: NP_000349.1	Swiss Prot Acc #: Q15582
Length (aa): N/A	Mol. Weight (Da): 74681	Chrom Location: N/A

Physical Appearance: Sterile filtered liquid formulation 1mg/ml.

Source/Host: E. Coli

Purity/Purification: Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.

Format: The BIGH3 recombinant Human is formulated 20mM Tris pH-8.

Stability: Transforming Growth Factor Beta Induced protein Recombinant Human although stable at 4 C for 30 days, should be stored desiccated below -20 C for periods greater than 30 days.
Please avoid Freeze/Thaw cycles.

Shipping: Products may be shipped on ice pack or dry ice.

TESTING: (secondary reagents and protocols )

Not Available

TGFBI PROTEIN TARGET DESCRIPTION:

Synonym Names for TGFBI protein: TGFBI; BIGH3; Transforming growth factor-beta-induced protein ig-h3, Beta ig-h3, Kerato-epithelin, RGD-containing collagen-associated protein, RGD-CAP, TGFBI, BIGH3, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, CDGG1.; Beta ig-h3; Kerato-epithelin; RGD-containing col; Transforming growth factor-beta-induced protein ig-h3

BIGH3 Recombinant Human (fourth FAS domain) produced in e.Coli is a single, non-glycosylated, polypeptide containing 135 amino acids (502-636) and having a molecular mass of 14.5 kDa.
The BIGH3 recombinant Human protein is purified by proprietary chromatographic techniques.

Transforming Growth Factor Beta Induced protein also known as TGFBI is an extracellular matrix protein induced by transforming growth factor (TGF)-beta 1. BIGH3 protein is involved in cell growth, cell differentiation, wound healing and cell adhesion. In addition, some missense mutations of BIGH3 were identified in families affected with human autosomal dominant corneal dystrophies. BIGH3 gene encodes for a 683 amino-acid protein containing an RGD motif and four internal repeated domains which have highly conserved sequences founded in several species (Fasciclin domain).

Function: Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation.

Subcellular Location: Secreted, extracellular space, extracellular matrix. Note=May be associated both with microfibrils and with the cell surface.

Tissue Specificity: Highly expressed in the corneal epithelium.

Induction: By TGF-beta.

Ptm: Gamma-carboxyglutamate residues are formed by vitamin K dependent carboxylation. These residues are essential for the binding of calcium (By similarity).

Disease: Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD) [MIM:121820]; also known as Cogan corneal dystrophy or map-dot-fingerprint type corneal dystrophy. EBMD is a bilateral anterior corneal dystrophy characterized by grayish epithelial fingerprint lines, geographic map-like lines, and dots (or microcysts) on slit-lamp examination. Pathologic studies show abnormal, redundant basement membrane and intraepithelial lacunae filled with cellular debris. Although this disorder usually is not considered to be inherited, families with autosomal dominant inheritance have been identified.

Disease: Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1) [MIM:121900]; also known as corneal dystrophy granular type. Inheritance is autosomal dominant. Corneal dystrophies show progressive opacification of the cornea leading to severe visual handicap.

Disease: Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1) [MIM:122200]. Inheritance is autosomal dominant.

Disease: Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB) [MIM:602082]; also known as corneal dystrophy of Bowman layer type 2 (CDB2).

Disease: Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB) [MIM:608470]; also known as corneal dystrophy of Bowman layer type 1 (CDB1).

Disease: Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A) [MIM:608471]. CDL3A clinically resembles to lattice corneal dystrophy type 3, but differs in that its age of onset is 70 to 90 years. It has an autosomal dominant inheritance pattern.

Disease: Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD) [MIM:607541]. ACD could be considered a variant of granular dystrophy with a significant amyloidogenic tendency. Inheritance is autosomal dominant.

Similarity: Contains 1 EMI domain.

Similarity: Contains 4 FAS1 domains.

OMIM: 121820; phenotype. [NCBI / EBI]
121900; phenotype. [NCBI / EBI]
122200; phenotype. [NCBI / EBI]
601692; gene. [NCBI / EBI]
602082; phenotype. [NCBI / EBI]
607541; phenotype. [NCBI / EBI]
608470; phenotype. [NCBI / EBI]
608471; phenotype. [NCBI / EBI]

Products similar to TGFBI protein:

Protein

BIGH3, Fasciclin domain 4, Protein

SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: TGFBI protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of TGFBI protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about TGFBI protein, all related information, articles, resources about TGFBI protein are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300

recombinant proteins

offered in our catalog.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved